Hot Flashes: What Could Be Causing Them

The Thermostat Theory: Why Hot Flashes Happen

Hot flashes originate in the hypothalamus, the brain's thermoregulatory center. In a normal state, the thermoneutral zone (the range of core body temperatures that triggers neither sweating nor shivering) spans roughly 0.4°C. Estrogen withdrawal narrows this zone to nearly zero, so even tiny temperature fluctuations trigger a full heat-dissipation cascade: peripheral vasodilation, sweating, and a subjective sensation of intense warmth [1].

Neurokinin B (NKB) and its receptor, NK3R, sit at the center of this mechanism. KNDy neurons in the arcuate nucleus release NKB in response to falling estrogen, directly activating heat-dissipation pathways [2]. This discovery led to the development of NK3R antagonists like fezolinetant, which the FDA approved in May 2023 specifically for moderate-to-severe vasomotor symptoms [3]. The narrowed thermoneutral zone model also explains why conditions unrelated to menopause (thyroid storm, certain tumors, drug reactions) can produce identical symptoms: anything that destabilizes hypothalamic thermoregulation or floods the bloodstream with vasoactive substances can mimic the classic hot flash.

A typical episode lasts 1 to 5 minutes. Frequency ranges from a few per week to dozens per day. Night sweats are the nocturnal equivalent and disrupt sleep architecture, contributing to fatigue, mood changes, and reduced quality of life.

Menopause and Perimenopause: The Leading Cause

Estrogen decline during the menopausal transition accounts for the vast majority of hot flashes. The Study of Women's Health Across the Nation (SWAN), a longitudinal cohort of 3,302 women followed for over 17 years, reported that the median total duration of vasomotor symptoms was 7.4 years, with a median persistence of 4.5 years after the final menstrual period [4]. Black and Hispanic women experienced longer symptom durations than white and Asian women, a disparity that persisted after adjusting for BMI, smoking, and socioeconomic factors.

Hot flashes typically begin during perimenopause, sometimes years before the last period. FSH levels above 25 IU/L combined with irregular cycles strongly suggest the menopausal transition. Serum estradiol below 30 pg/mL in a symptomatic woman over 45 is consistent with menopause, though single measurements have limited value because of day-to-day fluctuation.

Surgical menopause (bilateral oophorectomy) produces an abrupt estrogen drop and often causes more severe vasomotor symptoms than natural menopause. Women who undergo oophorectomy before age 45 without estrogen replacement face both intense hot flashes and elevated long-term cardiovascular risk, according to the 2022 Menopause Society position statement [5].

Thyroid Disorders

Hyperthyroidism mimics hot flashes closely. Excess thyroid hormone raises basal metabolic rate, increases heat production, and triggers peripheral vasodilation. Graves' disease, toxic multinodular goiter, and thyroiditis can all present with heat intolerance that patients describe as "hot flashes."

The distinguishing features: thyroid-driven heat intolerance tends to be constant rather than episodic, and it comes with tachycardia, tremor, weight loss, and anxiety. A suppressed TSH (below 0.1 mIU/L) with elevated free T4 confirms the diagnosis [6]. The American Thyroid Association guidelines recommend checking TSH as a first-line test in any patient with new-onset heat intolerance, even if menopause seems the obvious explanation [6].

Hypothyroidism, by contrast, does not cause hot flashes. But Hashimoto's thyroiditis can swing between hyper- and hypothyroid phases early in its course, producing intermittent heat episodes that confuse the clinical picture. Serial TSH measurements 6 to 8 weeks apart clarify the trajectory.

Medications That Trigger Hot Flashes

A long list of drugs cause or worsen vasomotor symptoms. The mechanism varies by drug class, but the result is the same: episodic flushing, sweating, and heat sensation.

Tamoxifen and aromatase inhibitors. Up to 80% of breast cancer survivors on tamoxifen report hot flashes, often rated as more severe than menopausal hot flashes [7]. Aromatase inhibitors (anastrozole, letrozole, exemestane) produce a similar effect by suppressing residual estrogen synthesis. These patients cannot use estrogen therapy, making non-hormonal alternatives (fezolinetant, oxybutynin, low-dose venlafaxine) the primary options.

SSRIs and SNRIs. Paroxetine, venlafaxine, and desvenlafaxine can both cause and treat hot flashes, depending on dose and context. Paroxetine 7.5 mg (Brisdelle) is FDA-approved for vasomotor symptoms, yet higher antidepressant doses of SSRIs list "sweating" and "flushing" as common adverse effects. The paradox reflects dose-dependent serotonergic modulation of the thermoregulatory center.

GnRH agonists and antagonists. Leuprolide, goserelin, and degarelix suppress gonadal steroids to castrate levels. Hot flashes occur in 50% to 80% of men on androgen deprivation therapy for prostate cancer and in women receiving GnRH agonists for endometriosis or fibroids [8].

Opioid withdrawal. Abrupt cessation of chronic opioid therapy triggers autonomic instability, including profuse sweating and hot flashes. Patients tapering opioids or on naltrexone may experience vasomotor episodes for weeks.

Other culprits. Niacin (nicotinic acid) causes prostaglandin-mediated flushing in up to 70% of users. Calcium channel blockers, nitrates, and calcitonin gene-related peptide (CGRP) pathways can also produce flushing, though the pattern differs from classic hot flashes.

Pheochromocytoma and Paraganglioma

Catecholamine-secreting tumors of the adrenal medulla (pheochromocytoma) or extra-adrenal paraganglia cause paroxysmal hypertension, headache, sweating, and flushing that patients often describe as hot flashes. The episodes can be spontaneous or triggered by physical exertion, anesthesia, or certain foods (tyramine-rich cheeses, red wine).

These tumors are rare (2 to 8 cases per million per year), but missing the diagnosis is dangerous. Hypertensive crisis during surgery or pregnancy can be fatal. The Endocrine Society clinical practice guideline recommends screening with plasma free metanephrines or 24-hour urine fractionated metanephrines in any patient with episodic hypertension plus sweating/flushing [9]. Sensitivity of plasma free metanephrines exceeds 96%. CT or MRI of the abdomen localizes the tumor once biochemical confirmation is obtained.

Carcinoid Syndrome

Neuroendocrine tumors, most commonly arising in the small intestine, secrete serotonin, histamine, and other vasoactive peptides. When hepatic metastases allow these substances to bypass first-pass metabolism, the result is carcinoid syndrome: episodic flushing (often violaceous rather than the red flush of menopause), diarrhea, wheezing, and right-sided heart valve disease.

Flushing episodes in carcinoid syndrome can be provoked by alcohol, stress, or certain foods. A 24-hour urine 5-HIAA (5-hydroxyindoleacetic acid) level above 25 mg per 24 hours has approximately 73% sensitivity and 100% specificity for carcinoid syndrome [10]. Serum chromogranin A supports the diagnosis but is less specific. Somatostatin receptor scintigraphy (Octreoscan) or gallium-68 DOTATATE PET/CT localizes the primary tumor and metastases [11].

This is a diagnosis that clinicians miss when they assume every flushing episode in a middle-aged patient is menopausal. The co-occurrence of diarrhea and flushing should always prompt a 5-HIAA measurement.

Infections and Systemic Inflammation

Tuberculosis, HIV, endocarditis, and lymphoma can all produce drenching night sweats that overlap clinically with menopausal hot flashes. The pattern differs: infectious and inflammatory night sweats tend to be continuous (every night, soaking through bedsheets) rather than intermittent, and they co-occur with fever, weight loss, or lymphadenopathy.

Brucellosis, a zoonotic infection endemic in parts of the Middle East, Central Asia, and Latin America, classically causes undulant fever with sweating episodes. In a febrile patient with occupational exposure (livestock workers, veterinarians), blood cultures and Brucella serology are indicated.

Lymphoma, particularly Hodgkin lymphoma, produces B-symptoms (fever, night sweats, unintentional weight loss exceeding 10% of body weight over 6 months). Any patient with new-onset drenching night sweats, especially combined with unexplained weight loss or palpable lymphadenopathy, warrants a complete blood count, lactate dehydrogenase, ESR, and chest imaging before attributing symptoms to hormonal change [12].

Hot Flashes in Men

Men experience hot flashes too. The most common trigger is androgen deprivation therapy (ADT) for prostate cancer. Bilateral orchiectomy and GnRH agonists both produce castrate testosterone levels (below 50 ng/dL), and 50% to 80% of these men report vasomotor symptoms that persist for the duration of therapy [8].

Outside of ADT, male hot flashes can signal hypogonadism from other causes: Klinefelter syndrome, pituitary adenomas, opioid-induced androgen deficiency, or testicular failure. A morning total testosterone below 264 ng/dL on two separate draws, per the American Urological Association guideline, supports the diagnosis of testosterone deficiency [13].

Treatment options for ADT-related hot flashes include low-dose medroxyprogesterone acetate (20 mg/day), gabapentin (300 mg three times daily), venlafaxine (75 mg/day), or acupuncture. A randomized trial of 167 men on ADT found that venlafaxine reduced hot flash frequency by 47% versus 28% with placebo at 6 weeks [14].

Diagnostic Workup: A Stepwise Approach

The differential diagnosis narrows quickly with a focused history and basic labs. Start with the clinical context.

Step 1: Characterize the episodes. Duration, frequency, triggers, time of day, associated symptoms (palpitations, diarrhea, headache, weight change). Episodic and self-limited episodes point toward vasomotor or catecholamine-driven causes. Constant heat intolerance suggests thyroid excess.

Step 2: Review the medication list. Tamoxifen, aromatase inhibitors, GnRH agonists, SSRIs, opioids, niacin, and nitrates are the most common drug-related causes. A temporal relationship between drug initiation and symptom onset clinches the diagnosis.

Step 3: Order baseline labs.

• FSH, estradiol (or testosterone in men) to confirm hormonal status
• TSH, free T4 to exclude thyroid disease
• CBC, ESR, LDH if B-symptoms are present
• Plasma free metanephrines if episodes are paroxysmal with hypertension
• 24-hour urine 5-HIAA if flushing co-occurs with diarrhea

Step 4: Image selectively. Adrenal CT/MRI for suspected pheochromocytoma. DOTATATE PET/CT for suspected carcinoid. Chest imaging if lymphoma is in the differential. Do not image routinely for isolated menopausal hot flashes.

The Endocrine Society recommends this layered approach to avoid expensive and unnecessary testing while catching dangerous mimics early [9].

Treatment: Matching Therapy to Cause

Menopausal vasomotor symptoms. Systemic estrogen therapy remains the most effective treatment, reducing hot flash frequency by 75% compared to placebo in the 2017 Cochrane systematic review of 24 trials (N=3,329) [15]. The 2022 Menopause Society position statement endorses hormone therapy for symptomatic women under 60 or within 10 years of menopause onset, barring contraindications (history of breast cancer, active cardiovascular disease, unexplained vaginal bleeding) [5].

For women who cannot take estrogen, fezolinetant 45 mg daily reduced moderate-to-severe hot flash frequency by 60% at week 12 in the SKYLIGHT 1 trial (N=501) versus 43% with placebo [3]. Paroxetine 7.5 mg, gabapentin 900 mg/day, and oxybutynin 2.5 mg twice daily are supported by randomized data as second-tier options.

Thyroid-driven episodes. Treat the underlying thyroid disease. Methimazole or propylthiouracil for Graves' disease. Beta-blockers (propranolol 20 to 40 mg three times daily) control symptoms while awaiting biochemical euthyroidism.

Drug-induced hot flashes. Dose reduction, drug substitution, or addition of a targeted therapy (gabapentin or venlafaxine for tamoxifen-related flashes) are reasonable strategies. Never discontinue tamoxifen for vasomotor symptoms alone without oncology input.

Pheochromocytoma. Alpha-blockade (phenoxybenzamine or doxazosin) followed by surgical resection. Medical therapy alone does not cure the tumor.

Carcinoid syndrome. Long-acting octreotide (Sandostatin LAR, 20 to 30 mg intramuscularly every 4 weeks) controls flushing and diarrhea in 50% to 70% of patients [11]. Telotristat ethyl (Xermelo) adds benefit for refractory diarrhea.

Lifestyle and Behavioral Strategies

Cognitive behavioral therapy (CBT) reduced hot flash bother ratings by 50% in a randomized trial of 140 breast cancer survivors, though it did not reduce objective frequency [16]. The effect persisted at 9 months. Clinical hypnosis showed similar benefit in a trial of 187 postmenopausal women, cutting hot flash frequency by 74% versus 17% with structured attention control [17].

Practical measures that have evidence behind them: keeping ambient temperature below 20°C at night, layered clothing, avoiding alcohol and spicy foods as triggers, and regular aerobic exercise. A 2019 randomized trial (N=261) found that 150 minutes per week of moderate-intensity exercise did not reduce hot flash frequency overall, but subgroup analysis showed a 28% reduction in previously sedentary women [18]. Weight loss of 10% or more is associated with reduced vasomotor symptoms in overweight women, based on data from the Women's Health Initiative.

Black cohosh, evening primrose oil, and soy isoflavones are popular supplements, but systematic reviews consistently show effect sizes no larger than placebo for hot flash reduction [15]. Patients asking about these supplements deserve a clear summary of the evidence rather than a dismissive "it doesn't work."

When to Worry: Red Flags That Demand Evaluation

Most hot flashes are benign. A subset signals something dangerous. Seek evaluation promptly if hot flashes co-occur with any of the following: unintentional weight loss exceeding 5% over 6 months, paroxysmal hypertension (systolic spikes above 200 mmHg), chronic watery diarrhea (raises carcinoid suspicion), palpable lymphadenopathy or persistent fever, onset in a male patient without known ADT exposure, or age under 40 without surgical menopause (consider primary ovarian insufficiency, which affects 1% of women before age 40) [19].

Primary ovarian insufficiency (POI) requires prompt diagnosis because of its implications for bone health and cardiovascular risk. The European Society of Human Reproduction and Embryology recommends hormone therapy until at least the average age of natural menopause (51 years) for women with POI [19].

Initial labs for a woman under 40 with hot flashes and irregular menses: FSH (two measurements 4 weeks apart, both above 25 IU/L confirms POI), estradiol, TSH, prolactin, karyotype if POI is confirmed, and anti-Müllerian hormone if fertility preservation is a concern.